Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease

Authors: Lepor N.E.; Gross S.B.1; Daley W.L.; Samuels B.A.; Rizzo M.J.; Luko S.P.; Hickey A.; Buchbinder N.A.; Naqvi T.Z.

Source: The American Journal of Cardiology, Volume 86, Number 1, 1 July 2000 , pp. 107-110(4)

Publisher: Elsevier

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Language: English

Document Type: Short communication

DOI: 10.1016/S0002-9149(00)00840-7

Affiliations: 1: aHeart Center of Los Angeles, , Los Angeles, California, USA

This article is hosted on another website.

You may be required to register, activate a subscription or purchase the article before you can obtain the full text.

Proceed

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A